Adam Friedman, M.D., Ph.D.
Dr. Friedman has been Scorpion Therapeutics’ President, Corporate Strategy & Business Development since September 2021, after serving as interim Chief Executive Officer between February 2021 and August 2021, as Executive…
Dr. Friedman has been Scorpion Therapeutics’ President, Corporate Strategy & Business Development since September 2021, after serving as interim Chief Executive Officer between February 2021 and August 2021, as Executive Vice President, Corporate Development & Operations from July 2020 until February 2021 and as Senior Vice President, Corporate Development & Operations between March 2020 and July 2020. Prior to joining Scorpion Therapeutics, Dr. Friedman served as the Director of Corporate Development at Raze Therapeutics, Inc., a company which he co-founded, between 2013 and 2019, and as President and Chief Executive Officer of Vivid Biosciences, LLC, an oncology platform discovery company of which he was the founder, between 2016 and 2019. Previously, Dr. Friedman was an Entrepreneur-in-Residence at Atlas Venture.
Dr. Friedman received his B.A. in Molecular Biology from Princeton University and received both his M.D. and Ph.D. in Genetics and Cell Biology from Harvard Medical School. Dr. Friedman trained in Pediatrics at Boston Children’s Hospital.